Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study

BACKGROUND: The risk of late distant recurrence (LDR) of estrogen receptor (ER)-positive breast cancer continues even after 5 years of endocrine treatment. Clinical Treatment Score after 5 years (CTS5) was developed and validated as a tool to assess the risk of LDR using data from Tamoxifen, Arimide...

Descripción completa

Detalles Bibliográficos
Autores principales: Dejthevaporn, Thitiya, Patanayindee, Panchanin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392218/
https://www.ncbi.nlm.nih.gov/pubmed/37533837
http://dx.doi.org/10.1177/11782234231186869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392218/
https://www.ncbi.nlm.nih.gov/pubmed/37533837
http://dx.doi.org/10.1177/11782234231186869

Ejemplares similares